Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • "Best of" Collection
      • Editors' Picks
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Cancer Prevention Research
Cancer Prevention Research
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • "Best of" Collection
      • Editors' Picks
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Chemoprevention and Biological Therapies

Abstract CN13-04: Obesity, insulin resistance, hyperglycemia, and cancer: A novel role for metformin as an anticancer drug

Ann D. Thor and Xin‐Sheng Deng
Ann D. Thor
University of Colorado Denver and School of Medicine, Aurora, CO.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Xin‐Sheng Deng
University of Colorado Denver and School of Medicine, Aurora, CO.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1158/1940-6207.PREV-09-CN13-04 Published January 2010
  • Article
  • Info & Metrics
Loading
Abstracts: AACR International Conference on Frontiers in Cancer Prevention Research‐‐ Dec 6–9, 2009; Houston, TX

Abstract

Dysregulation of glucose homeostasis (metabolic syndrome and diabetes) and fatty acid metabolism (obesity, particularly of the upper body) have reached epic proportions worldwide, increasing the risk of both cardiovascular disease and cancer. These alterations promote breast cancer in two major risk subgroups, post‐menopausal women (who develop ER+ breast cancers (1)) and premenopausal women of color (who are more likely to present with advanced stage disease, have a poorer prognosis and develop the ‘basal’ subtype of cancer (2)). Because obesity and type II diabetes are potentially modifiable risk factors for breast cancer incidence and outcome, further understanding of these processes should provide insights that can be used to devise interventional or pharmacologic strategies. Reported mechanisms by which these chronic diseases induce breast cancer are diverse, including but not limited to: upregulation of the insulin/insulin‐like growth factor (IGF) system (3), shifts in cytokines and adipokines, which act as endocrine, paracrine and autocrine factors (4), alterations of energy sensing mechanisms involving the AMP‐activated protein kinases (AMPK (5)), metabolic reprogramming of stem and progenitor cells involving “aerobic glycolysis, de novo lipid biosynthesis and glutamine‐dependent anaplerosis” (6, 7), upregulation of estrogen and androgen associated signaling (particularly in peri‐ and post menopausal women), and alterations of molecular/genetic factors which induce shifts in cellular (lipid and glucose) metabolism (8).

Hormonal factors, especially estrogen and progesterone (with or without binding to cognate receptors) promote breast cancer and may act through induction of cellular proliferation or effects on stem cell growth (9). Insulin and insulin‐like growth factors (which are typically secreted at levels higher than insulin) are typically upregulated early on in type II diabetes and in patients with metabolic syndrome and obesity. Receptors for these important growth hormones are expressed ubiquitously in human cells, and frequently upregulated in breast cancers of all molecular subtypes. Insulin and IGF‐1 have been shown to activate tyrosine kinase growth receptor pathways, upregulate the insulin regulated substrate (IRS1), activate the Ras‐Raf‐mitogen‐activated protein (MAP) kinase cascade and phosphoinositol‐3 kinase/Akt (PI3K‐Akt) signaling (3).

Cancerous cells have long been known to have higher rates of glucose uptake (from the systemic and localized microenvironment) and an increase in aerobic glycolysis, resulting in local production of lactate and ATP (known as the Warburg effect). In 1956, Oto Warburg postulated that alterations of glucose metabolism may represent the “origin of cancer” (10). He later compared the increased glycolytic activity of cancer cells to that of early embryonic cells, setting the stage for modern theories of cancer stem cells (11). Ironically, tissue culture media typically contains high levels of glucose (∼17mM); as compared to physiological (5mM), metabolic syndrome (7mM), and diabetic (10mM) concentrations. This means that our culture systems drive aerobic glycolysis and may select subpopulations that thrive under these conditions. This “metabolic reprogramming” enables cancer cell growth and metastasis, through several critical mechanisms: 1) aerobic glycolysis enables energy production and survival under hypoxic conditions; 2) the production of lactate facilitates tumor invasion and suppresses anti‐cancer immunity; 3) the production of NADPH enhances anti‐oxidant defenses against chemotherapy; and 4) glycolytic pathway intermediates promote cell proliferation providing a growth advantage.

Epidemiological data indicates that diabetic and pre‐diabetic women treated with metformin (but not other anti‐diabetic agents) have a lower incidence of breast cancer, whereas diabetic patients treated with other agents do not (12). In a recent study of breast cancer patients administered neoadjuvant chemo‐therapy, diabetic patients who also received metformin had the highest pathologic complete response rate (pCR 24%), as compared to non‐diabetic patients (pCR 16%) and diabetic patients treated with agents other than metformin (pCR 8%) (13).

We have investigated the biological and molecular effects of hyperglycemia, with or without the addition of metformin, insulin or leptin, using cell lines representing all molecular subtypes of breast cancer. The anti‐diabetic drug metformin induces growth inhibition (S phase arrest) and apoptosis of basal (ER−, PR−, HER2−, EGFR+, CK5+) breast cancer cell lines in vivo and in vitro (14). In contrast, metformin is less effective in growth inhibition (it induces a partial G1 arrest at higher doses) and does not induce apoptosis in other breast cancer subtypes (e.g. luminal A (ER+, PR+, HER2−); luminal B (ER+, PR+, HER2+) or HER2 (ER−, PR, HER2+) (15). Luminal A and basal breast cancer cell lines showed the most proliferation in response to supraphysiologic glucose, compared to luminal B and HER2 lines which were not differentially responsive. Metformin abrogated glucose induced mitogenesis across all glucose concentrations, with the most in basal cell lines derived from African American patients. Metformin was less effective in basal cells derived from Caucasians and in luminal A cells. In basal cells, glucose increased EGFR, pEGFR, IGF1R, pIGF1R, AKT and pAKT, IRS2, the cyclins D1, E an A and decreased AMPK, pAMPK, pMAPK in a dose dependent manner. The addition of metformin to glucose containing media blocked the aforementioned changes in EGFR, pEGFR, IGF1R, pIGF1R, AKT, MAPK, pMAPK, AMPK, pAMPK and Cyclin D1. Metformin had a variable effect on the other molecular breast cancer subtypes grown under high glucose conditions. All basal breast cancer cell lines were uniformly resistant to the mitogenic effects of leptin and insulin (despite expressing the cognate receptors), across a wide range of glucose concentrations. In contrast, both leptin and insulin promoted the growth of luminal A and to a lesser extent luminal B and HER2 cancer cells. Metformin partially abrogated the growth induced by insulin and leptin.

In conclusion, basal breast cancer cell lines showed the most significant mitogenesis in response to glucose, whereas they were uniformly resistant to leptin and insulin. This effect of both glucose and metformin were most pronounced in lines derived from minority patients. Luminal A type cell lines also showed marked growth induction by glucose, but unlike basal cells they also showed growth induction with leptin and insulin. These data are consistent with the molecular subtype and ethnicity associated variables linking obesity and diabetes to breast cancer risk and outcomes‐because the molecular subtypes of luminal A and basal are increased in women with these metabolic defects.

Citation Information: Cancer Prev Res 2010;3(1 Suppl):CN13-04.

  • Copyright © January 7, 2010, American Association for Cancer Research
Previous
Back to top
January 2010
Volume 3, Issue 1 Supplement
  • Table of Contents

Sign up for alerts

Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Prevention Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Abstract CN13-04: Obesity, insulin resistance, hyperglycemia, and cancer: A novel role for metformin as an anticancer drug
(Your Name) has forwarded a page to you from Cancer Prevention Research
(Your Name) thought you would be interested in this article in Cancer Prevention Research.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Abstract CN13-04: Obesity, insulin resistance, hyperglycemia, and cancer: A novel role for metformin as an anticancer drug
Ann D. Thor and Xin‐Sheng Deng
Cancer Prev Res January 7 2010 (3) (1 Supplement) CN13-04; DOI: 10.1158/1940-6207.PREV-09-CN13-04

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Abstract CN13-04: Obesity, insulin resistance, hyperglycemia, and cancer: A novel role for metformin as an anticancer drug
Ann D. Thor and Xin‐Sheng Deng
Cancer Prev Res January 7 2010 (3) (1 Supplement) CN13-04; DOI: 10.1158/1940-6207.PREV-09-CN13-04
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
Advertisement

Related Articles

Cited By...

More in this TOC Section

Chemoprevention and Biological Therapies

  • Abstract PR05: Low dose aspirin that reduces mortality from lung adenocarcinoma inhibits both platelet COX-1 and the biosynthesis of PGE2
  • Abstract PR13: Circadian/melatonin disruption by dim light at night drive chemotherapy resistance in breast cancer
  • Abstract PR09: Intermittent dosing regimens maintain efficacy of several cancer preventing drugs
Show more Chemoprevention and Biological Therapies

Oral Presentations - Invited Abstracts

  • Abstract IA01: The global impact of environmental carcinogenesis and interventions for prevention
  • Abstract IA18: The exposome and cancer
  • Abstract IA17: Challenges and opportunities in environmental carcinogenesis: The NIEHS perspective
Show more Oral Presentations - Invited Abstracts

Invited Abstracts - Stromal Targets for Breast Cancer Prevention

  • Abstract CN13-03: Postnatal breast involution as a highly targeted window for breast cancer prevention
  • Abstract CN13-05: A new resource to accelerate research into the cause and prevention of breast cancer: The Love/Avon Army of Women
Show more Invited Abstracts - Stromal Targets for Breast Cancer Prevention
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook   Twitter   LinkedIn   YouTube   RSS

Articles

  • Online First
  • Current Issue
  • Past Issues

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Cancer Prevention Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Cancer Prevention Research
eISSN: 1940-6215
ISSN: 1940-6207

Advertisement